Independent research performed at the University of St. Andrews in the UK has reportedly demonstrated the effectiveness of Alfacyte in-vitro against SARS-CoV-2.
According to an Oct. 6, 2020 press release, independent research performed at the University of St. Andrews in the United Kingdom has reportedly demonstrated the effectiveness of Alfacyte in-vitro against SARS-CoV-2.
Alfacyte, a unique synthetic Interferon from ILC Therapeutics, is claimed to be more effective at preventing the spread of SARS-CoV-2 in cell culture when compared with other commercially available Interferons. The research into the effectiveness of Alfacyte is being led by Dr. Catherine Adamson, a specialist in viral diseases at the University of St. Andrews.
“This [research] is a hugely exciting development and it demonstrates that there is a significant difference in the bioactivity of Interferon sub types against coronaviruses,” said Adamson in the press release. “These differences may have important therapeutic implications for COVID-19.”
“COVID-19 and other coronaviruses have spent a lot of evolutionary energy trying to protect themselves against the Interferon alpha because overcoming the innate immune system is their main concern,” added Prof. William Stimson, founder and chief scientific officer at ILC Therapeutics, in the press release. “Timing is everything and by delivering a powerful Interferon like Alfacyte to the airways using a nebulizer we hope to accelerate and support the innate immune defenses and prevent viral infection spreading and worsening.”
Further tests are being conducted on Alfacyte by ILC Therapeutics, which is hoping to proceed to clinical trials in 2021.
Source: ILC Therapeutics
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.